to go to the previous page
Head and Neck: Neck Management, Novel Functional Imaging,Toxicity, Biologic Therapy
Wednesday, November 4, 2009
Click the plus sign to see more detailed information
about each speaker.
Andy Trotti, MD
Professor and Director of Clinical Trials for Radiation Oncology
Moffitt Cancer Center
Dr. Trotti is a Professor and Director of Clinical Trials in Radiation Oncology at the Moffitt Cancer Center and is recognized for his expertise in Head and Neck (H&N) cancer and in the adverse effects of cancer treatment. His interests include improving the efficacy of radiotherapy in head and neck cancer clinical trials through integration of fractionation, cytotoxic agents and biologics. He currently serves as the Co-Chair of the NCI H&N Steering Committee responsible for development and approval of Phase II and III trials. Dr. Trotti is also Co-Chair of the Head and Neck Committee for the Radiation Therapy Oncology Group (RTOG), serves on the AJCC Executive Committee and the NCCN H&N Committee. In June 2008 Dr. Trotti delivered the honorary annual Wharton Lecture at Princess Margaret Hospital on the “Evolution of Adverse Event Reporting in Oncology.” He has co-authored several landmark RTOG studies of fractionation and organ preservation and is recognized for his work in developing the NCI adverse event (AE) grading dictionaries (NCI-CTCAE) now widely used in oncology. Dr. Trotti is currently leading initiatives to develop AE reporting standards and new methods to summarize, analyze and display adverse event data.
Quynh-Thu Le, M.D., Professor, Stanford School of Medicine
Audio Synchronized to PowerPoint